Research programme: trioxaquines - PALUMED/sanofi-aventis

Drug Profile

Research programme: trioxaquines - PALUMED/sanofi-aventis

Alternative Names: DU1302; PA 1103; SAR 116242

Latest Information Update: 08 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PALUMED; sanofi-aventis
  • Developer PALUMED; Sanofi
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 22 Oct 2008 Sanofi-aventis and Medicines for Malaria Venture enter into a collaboration to accelerate research and development of new antimalarial arugs
  • 20 Feb 2007 Preclinical trials in Malaria in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top